Earnings season continues to drive volatility as TCS flags margin pressure despite AI growth, while NCC slips 5.5% despite a major order win. Lupin gains on FDA approvals, but Jaykay Enterprises plunges 8.8% on subsidiary funding news.

Tata Consultancy Services

• Earnings: Q2FY27 net profit rose to ₹13,884 crore, but EBIT margin dipped to 23.98%, missing estimates due to seasonal factors and acquisition dilution. Annualized AI revenues crossed US$ 3.1 billion. Stock closed at ₹2076.00 in the previous session, down 0.21%.
• Deal: Acquired Best Buy India GCC for ₹1 lakh to establish an AI Native Capability Center in Bengaluru, transitioning approximately 450 employees.
• Management: Reported hiring 10,000 fresh graduates in Q2, signaling continued campus recruitment activity.

Pace Digitek

• Fund raise: Board meeting scheduled for October 12 to consider raising funds via Non-Convertible Debentures on a private placement basis. Stock closed at ₹161.85 in the previous session, down 2.18%.
• Order Book: Order book grew to over ₹11,000 crore in FY26, with the energy segment accounting for 88.7% of post-listing inflows.
• Corporate action: Trading window closed from October 1 ahead of Q2FY27 results announcement.

NCC

• Order Book: Secured a ₹1,286.03 crore order from Hyderabad Growth Corridor Limited for Radial Road-2 construction. Additionally, won two contracts worth ₹500.22 crore in September. Stock closed at ₹119.93 in the previous session, down 5.48%.

PN Gadgil Jewellers

• Earnings: Q2FY27 revenue rose 22.4% YoY, driven by a 31.1% expansion in the retail segment. Rakhi sales value surged 142% YoY. Stock closed at ₹586.30 in the previous session, down 1.80%.
• Deal: Completed acquisition of Silvostyle Jewellers Limited, making it a wholly owned subsidiary effective October 1, 2026.

KEC International

• Regulatory: Received a ₹6.79 crore penalty from Mali tax authorities regarding offshore supplies from 2020-2021. The company contests the demand, citing tax exemptions. Stock closed at ₹349.60 in the previous session, down 3.56%.

Lupin

• Product launch: Launched Formoflo-G MDI, the world's first fixed-dose triple combination inhaler for COPD in India, targeting over 55 million patients. Stock closed at ₹1936.90 in the previous session, down 3.78%.
• Regulatory: Secured US FDA approval for Phytonadione Injectable Emulsion USP, with an estimated annual U.S. market of $52.3 million.
• Corporate action: Subsidiary Multicare Pharmaceuticals Philippines completed a buyback, becoming a wholly owned entity.

Tilaknagar Industries

• Management: CFO Rajesh Choudhary resigned on October 8, citing external opportunities. Deputy CFO Anil Singal has been elevated to Senior Management Personnel. Stock closed at ₹548.05 in the previous session, down 0.63%.

Jubilant Pharmova

• Fund raise: Board meeting scheduled for October 12 to consider raising funds via Non-Convertible Debentures, potentially requiring shareholder approval. Stock closed at ₹932.20 in the previous session, down 4.35%.

Jaykay Enterprises

• Deal: Granted a ₹100 crore unsecured loan to wholly owned subsidiary JK Defence & Aerospace at 10% interest. Also invested ₹25 crore via rights issue proceeds. Stock closed at ₹240.24 in the previous session, down 8.81%.
• Corporate action: Passed all 13 AGM resolutions, including adoption of FY26 financial statements despite a modified audit opinion.

Bottom Line

Construction stocks faced profit-taking despite order wins, while pharma names like Lupin saw mixed reactions to regulatory updates. IT majors remain under pressure on margin concerns, and small-cap defensives like Jaykay Enterprises face scrutiny on related-party transactions.